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Allogeneic hematopoietic transplantation is an effective
treatment for a range of hematologic, immune, metabolic, and
neoplastic diseases. The procedure generally involves adminis-
tration of a myeloablative preparative regimen followed by
transplantation of a source of hematopoietic stem cells to
restore hematopoiesis. Hematopoietic stem and progenitor
cells can be collected from a number of potential sources for
transplantation, including bone marrow, granulocyte colony-
stimulating factor (G-CSF)–mobilized peripheral blood, cord
blood, and fetal hematopoietic tissues. Each source of cells has
different characteristics and is associated with a different pace
of hematologic recovery as well as varying rates of acute and
chronic graft-versus-host disease (GVHD).
Bone marrow transplantation has been the accepted
source of hematopoietic cells for allogeneic transplantation
during the past several decades. Within the past decade,
G-CSF–mobilized peripheral blood stem cells (PBSCs) have
been widely evaluated for allogeneic transplantation [1-4].
Several reports of transplants from HLA-identical siblings
have indicated that allogeneic PBSC transplants produce
more rapid recovery of granulocytes and platelets than mar-
row grafts, with possibly less regimen-related toxicity and
improved treatment-related mortality [5-8]. Blood stem cell
collections generally contain a greater number of CD34+
cells and approximately 1 log more T lymphocytes than a
bone marrow harvest, which could potentially affect the
development of acute or chronic GVHD or graft-versus-
leukemia (GVL) effects [1]. In many studies of stem cell
transplantation, the rate of acute GVHD has not differed
from that seen with bone marrow transplantation, but the
rate of chronic GVHD has increased [9-12]. In some stud-
ies, transplantation using blood stem cells decreased the risk
of relapse of the underlying malignancy [2,13]. 
A recent analysis by the International Bone Marrow
Transplant Registry comparing allogeneic blood stem cells
with bone marrow transplants showed that blood stem cells
produced more rapid granulocyte and platelet recovery, and
1-year survival was improved in patients with high-risk
leukemias [14]. Patients with early leukemias are at lower
risk for transplantation-related mortality, and 1-year survival
rates in patients who receive blood stem cells are similar to
those in patients who receive bone marrow. Several random-
ized trials have been conducted comparing blood stem cell
and bone marrow transplants; results were usually consistent
with those previously reported, although the studies lacked
statistical power to address whether chronic GVHD is
increased with stem cell transplantation [13,15,16]. 
Allogeneic transplantation using blood stem cells from
unrelated donors has also been studied and has shown simi-
lar advantages for hematologic recovery. Unrelated donor
transplant recipients are at higher risk for acute GVHD
than patients who receive transplants from genotypically
matched siblings; preliminary data indicate that the rate of
acute GVHD in these patients is similar for blood stem cell
transplants and bone marrow transplants [17].
Systemic G-CSF administration has also been reported
to increase the repopulating ability of murine bone marrow
cells [18] and myeloid progenitor cells in humans [19,20].
However, in other preclinical studies, exposure to G-CSF or
other cytokines failed to enhance hematopoietic repopulat-
ing potential [21]. Janssen et al. reported that granulocyte
recovery after autologous transplantation using bone marrow
collected after systemic G-CSF treatment (ie, G-CSF–primed
bone marrow) was similar to that after transplantation using
G-CSF–mobilized PBSCs [22]. Several groups have exam-
ined the use of G-CSF–primed bone marrow collections for
human autologous hematopoietic transplantation, reporting
granulocyte and platelet recovery similar to that seen after
blood stem cell transplantation [23-25].
G-CSF–primed bone marrow has been considered for
allogeneic transplantation. G-CSF priming is not expected
to affect the numbers of lymphocytes in the collected mar-
row and hence might not affect the rate of chronic GVHD
in the same manner as allogeneic blood stem cells. In
murine models, donor G-CSF administration has been
associated with modulation of T cells from a T helper
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(Th) 1 to a Th2 phenotype, thereby decreasing the inci-
dence of GVHD [26].
Isola et al. [27] reported a pilot study of allogeneic
transplantation using G-CSF–stimulated bone marrow from
related donors. Stimulated bone marrow infusions contained
a similar number of CD34+ cells as unstimulated marrow
but higher numbers of granulocyte colony-forming units.
Patients receiving stimulated bone marrow experienced
prompt and durable engraftment. In this small pilot study of
10 patients, hospitalization appeared to be shortened, and
none of the patients had severe chronic GVHD, although
the duration of follow-up was short.
In this issue of Biology of Blood and Marrow
Transplantation, 3 studies of G-CSF–primed allogeneic bone
marrow transplantation are presented. Serody et al. (pp 434-
440) report a sequential nonrandomized analysis of patients
receiving either G-CSF–mobilized PBSCs or G-CSF–stimu-
lated bone marrow. G-CSF was administered daily for 4 days
before marrow harvest. As expected, there was a 1-log lower
T-cell dose in the group receiving bone marrow grafts.
Granulocyte recovery was similar between groups, but there
was a trend toward faster platelet recovery in the PBSC
group. Patients who received primed bone marrow group
had significantly less chronic GVHD, which resulted in
fewer late deaths. There was also a trend toward less acute
GVHD in PBSC patients, although the difference was not
statistically signiﬁcant. There was a trend toward improved
survival in high-risk PBSC recipients, possibly from an
increased GVL effect associated with chronic GVHD.
Couban et al. (pp 422-427) report a single-arm study of
29 patients who received G-CSF–primed bone marrow.
Donors received ﬁlgrastim daily for 4 days before harvest.
The median time for bone marrow aspiration was reported
to be close to half that of historical controls and suggests a
potential beneﬁt to donors. Faster recovery of granulocytes
and platelets was reported for the G-CSF–primed group, but
this benefit did not improve secondary end points such as
length of stay in the hospital. In contrast, Isola et al. (pp 428-
433) report on 17 patients who received G-CSF–primed
bone marrow transplants and compare these patients to 112
controls treated with steady-state bone marrow. In this study,
more rapid neutrophil recovery was associated with short-
ened hospitalization time; platelet recovery was not
improved. Again, faster engraftment was demonstrated with-
out an increase in GVHD or mortality.
In these 3 reports, a total of 72 patients received G-CSF–
mobilized bone marrow. These preliminary data suggest
that G-CSF–primed bone marrow allows faster engraftment
than steady-state marrow. Platelet recovery was more vari-
able than granulocyte recovery, and larger comparative stud-
ies are required to determine whether G-CSF–primed bone
marrow transplants will produce platelet recovery compara-
ble to that seen with blood stem cell grafts. The data also
suggest that primed marrow may be associated with less
chronic GVHD than PBSCs.
Marvoudis et al. [28] raised some concern about delayed
graft failure in their study of G-CSF–primed marrow sub-
jected to CD34+ selection. One hypothesis for this observation
was that graft failures were attributable to T-cell depletion, a
well-established risk. Graft failure has not been a problem in
other studies that did not involve T-cell depletion of the graft.
Several issues should be considered with G-CSF–
primed bone marrow transplantation. The biologic mecha-
nisms of G-CSF–priming effects need to be defined. Are
there separate effects on stem cells compared with more
mature progenitor cells? Are progenitors and stem cells acti-
vated or expanded by G-CSF treatment? The optimal
length of G-CSF treatment is also uncertain. G-CSF mobi-
lizes progenitor cells into the blood after 4 days [1]; it is pos-
sible that longer treatment may deplete stem and progenitor
cells from a bone marrow harvest. In the Couban et al. and
Serody et al. studies, G-CSF was administered for 4 days
before bone marrow harvest; hematologic recovery was
rapid, and graft failure did not occur.
Recent data suggest that allogeneic PBSCs and bone mar-
row are not simply interchangeable sources of hematopoietic
grafts. The increase in GVHD associated with PBSC trans-
plants appears to correlate with an increased GVL effect [29]
and improved relapse-free survival in high-risk patients
[14,15]. Patients who have nonmalignant diseases or malig-
nancies with a low risk of recurrence may beneﬁt from the
lower incidence of chronic GVHD seen with bone marrow
transplantation. The ultimate role of G-CSF–primed bone
marrow transplantation will depend on the effect of such
priming on engraftment, hematopoietic recovery, incidence of
acute and chronic GVHD, and risk of malignancy relapse in
each disease setting. Preliminary data suggest that primed
marrow will shorten the pancytopenic phase. The incidence of
acute and chronic GVHD appears to be similar to that seen
with unstimulated marrow. Whether G-CSF–primed bone
marrow transplants will have more clinically relevant beneﬁts,
such as shorter hospital stays or decreased morbidity, has yet
to be determined.
It is also important to consider the marrow donor [30].
The pilot studies presented do not report complications
occurring in G-CSF–primed bone marrow donors. It is
important to definitively confirm that donor risks are not
increased with this approach.
Controlled clinical trials and longer patient follow-up
are required to deﬁnitively assess the incidence of chronic
GVHD. G-CSF–primed marrow should be compared with
steady-state marrow in standard- or low-risk patients and
with PBSCs in high-risk patients. Larger numbers of
patients with extended follow-up times are required to
determine whether small but clinically meaningful differ-
ences in hematopoietic recovery will occur and whether a
difference in chronic GVHD can be demonstrated. Because
of the association of chronic GVHD and graft-versus-
malignancy effects, the primary end point of controlled
studies should be patient survival, adjusted for quality of life.
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